AC
IMVT icon

AXQ Capital’s Immunovant IMVT Stock Holding History

AXQ Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Sell
16,113
-5,959
-27% -$182K 0.07% 417
2026
Q1 		$548K Buy
+22,072
New +$571K 0.07% 387
2025
Q2 		– Sell
-11,453
Closed -$196K – 663
2025
Q1 		$196K Buy
+11,453
New +$240K 0.08% 401
2023
Q2 		– Sell
-26,727
Closed -$415K – 430
2023
Q1 		$415K Buy
+26,727
New +$464K 0.16% 218

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AXQ Capital's IMVT Position: Q2 2026 in Review

AXQ Capital reduced its Immunovant (IMVT) stake by 27% in Q2 2026, selling an estimated $182K and leaving 16,113 shares worth $621K. The position accounts for 0.07% of the portfolio, ranked #417.

AXQ Capital first reported a position in IMVT in Q1 2023 and has held it in 4 quarters since. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • AXQ Capital held 16,113 shares of Immunovant worth $621K as of Q2 2026.
  • AXQ Capital sold 5,959 Immunovant shares in Q2 2026, an estimated $182K.
  • Immunovant made up 0.07% of AXQ Capital's portfolio in Q2 2026, its #417 holding.
  • AXQ Capital first reported a position in Immunovant in Q1 2023 and has held it in 4 quarters since.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.